[Evidence of raloxifene on postmenopausal osteoporosis].
Okano
Hiroya
H
Department of Obstetrics and Gynecology, Tokyo Women's Medical University.
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism; D001943:Breast Neoplasms / Q000517:prevention & control; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control
D050071:Bone Density Conservation Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride